Marketing-Börse PLUS - Fachbeiträge zu Marketing und Digitalisierung
print logo

Prostate Cancer Market Tracking and Analysis of Competitive Developments by 2027

Market Research Future has recently declared the expansion of a new research study to its thorough collection of research reports.
Karishma s | 09.11.2018
© Karishma s
Market Research Future has recently declared the expansion of a new research study to its thorough collection of research reports “Worldwide Prostate Cancer Market Research Report 2018”.

The report for Global Prostate Cancer Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance.

The global prostate cancer market is showing the steady growth; mainly owing to increase in patient population. According to report published by Centers for Disease Control and Prevention, in 2014, there were around 172,258 men in the United States, who diagnosed with prostate cancer and around 28,343 men died from prostate cancer.

These rising number of prostate cancer create an opportunity for the player to introduce innovative treatment option.

GET FREE SAMPLE REPORT AT https://www.marketresearchfuture.com/sample_request/1580

Prostate Cancer Market is highlighted by further Key Acquisitions

OncoGenex Pharmaceuticals Inc. (U.S.)
Bayer Pharma AG (Berlin)
Progenics Pharmaceuticals, Inc. (U.S.)
Tolmar Inc. (U.S.)
OncBioMune Pharmaceuticals Inc. (U.S.)
Endo Pharmaceuticals Inc. (U.S.)
Tokai Pharmaceuticals, Inc. (U.S.)
These are some of the leading players at the cutting edge of the competition in the market of prostate cancer, globally.

Major Restraining Factors affecting the Market Growth

Companies are continuously invent new treatment to capture the global market. Thus players invest more in research and development activities.

In this regards, Bayer Pharma AG announced that they have many drugs for the treatment of prostate cancer in there pipeline such as Radium-223 dichloride and BAY 1841788 (ODM-201, AR antagonist).

Progenics Pharmaceuticals, Inc., 2015, acquired Exini Diagnostics AB in order to support its imaging and therapeutic agents with sophisticated analytical tools and other technologies to help patients and physicians understand, target and treat prostate cancer.

These companies are more investing in research and development program to provide the best treatment option, which help them to keep ahead with their competitor.

These acquisitions help companies to provide better treatment opportunity in the market and hence improve the quality of life for the people around the world.

Global Prostate cancer Market - Regional Analysis

According to Prostate cancer Foundation, it is the most common type of cancer in United States. The Older you are more chance of getting diagnosed with prostate cancer. 1 in 8 men get diagnosed with this type of cancer at some points of age.

According to American Cancer Society, in 2017, it is estimate that around 161,360 new cases of prostate cancer will get diagnosed and around 26,730 death occurs owing to prostate cancer in United States.

Europe is also consider huge market for prostate cancer market players, owing to present of huge population affected with disease.

Asia Pacific region are considering the growing market, owing to presence of huge population suffering with prostate cancer.

OBTAIN REPORT DETAILS @ https://www.marketresearchfuture.com/reports/prostate-cancer-market-1580

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com